Online inquiry

IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11081MR)

This product GTTS-WQ11081MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF1 gene. The antibody can be applied in Pigmented villonodular synovitis (PVNS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000757.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1435
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11081MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8290MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ5306MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ15215MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ13956MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ11520MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ15773MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ4556MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ15877MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XMT-1536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW